Peritoneal Nebulization of Ropivacaine for Pain Control After Laparoscopic Colectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

130 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess if intraperitoneal nebulization of Ropivacaine 150 mg produces better postoperative pain control than Saline nebulization after laparoscopic colectomy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intraperitoneal Ropivacaine Nebulization for Pain Control After Laparoscopic Surgery

NCT01143025

Laparoscopic Cholecystectomy

COMPLETED PHASE3

Local Anesthetic Nebulization for Pain Control After Laparoscopic Cholecystectomy

NCT01247857

Laparoscopic Cholecystectomy

COMPLETED PHASE3

Local Anesthetic Nebulization and Instillation for Pain Control After Laparoscopic Surgery

NCT01248819

Laparoscopic Cholecystectomy

COMPLETED PHASE3

Impact of Intraperitonael Nebulization of Local Anesthetic on Postoperative Pain Associated With Laparoscopic Surgery

NCT01512914

Gynecologic Laparoscopic Surgery

COMPLETED PHASE3

Intraperitoneal Ropivacaine Nebulization for Pain Control After Gynecologic Laparoscopic Surgery

NCT01142622

Ovarian Cysts

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recently intraperitoneal nebulization of local anesthetic has been used as an alternative to direct intraperitoneal instillation. Intraperitoneal aerosolization of Bupivacaine 50 mg after laparoscopic cholecystectomy significantly reduced postoperative pain, morphine consumption and incidence of postoperative nausea and vomiting and it is associated with rapid mobilization compared with patients receiving direct instillation of Bupivacaine 50 mg or placebo.

In a recent study the investigators found that nebulization of Ropivacaine 30 mg with the AeronebPro® before or after laparoscopic cholecystectomy and gynecologic laparoscopic surgery reduces postoperative pain and morphine consumption. Patients receiving preoperative nebulization of Ropivacaine presented significantly less postoperative pain (-50% clinical setting) and consumed significant less morphine (-50% and -40% respectively) than patients in control groups during the first 48 hours after surgery.

The effects of peritoneal nebulization of ropivacaine during laparoscopic colectomy on pain control and morphine consumption were not evaluated.

The investigators hypothesize that intraperitoneal nebulization of Ropivacaine may produce better pain control and less morphine consumption than nebulization of saline after laparoscopic colectomy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ropivacaine 150 mg

Nebulization of Ropivacaine 150 mg in the peritoneal cavity with the Aeroneb Pro system

Group Type EXPERIMENTAL

Ropivacaine 150 mg

Intervention Type DRUG

Nebulization of Ropivacaine 150 mg in the peritoneal cavity

Saline 15 ml

Nebulization of Saline 15 ml in the peritoneal cavity with the Aeroneb Pro system

Group Type PLACEBO_COMPARATOR

saline 15 ml

Intervention Type DRUG

Nebulization of saline 15 ml in the peritoneal cavity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ropivacaine 150 mg

Nebulization of Ropivacaine 150 mg in the peritoneal cavity

Intervention Type DRUG

saline 15 ml

Nebulization of saline 15 ml in the peritoneal cavity

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nebulization Ropivacaine Nebulization Saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Females and Males 18-80 years old
* ASA Score I (American Society of Anesthesiologists classification : a normal healthy patient.
* ASA Score II (American Society of Anesthesiologists classification): A patient with mild systemic disease
* ASA Score III (American Society of Anesthesiologists classification): A patient with severe systemic disease
* Patients scheduled for oncological laparoscopic colectomy
* Patients who do not use opioids analgesic drugs before surgery
* Patients without cognitive impairment or mental retardation

Exclusion Criteria

* Females and Males under 18 or over 80
* ASA Score IV (American Society of Anesthesiologists classification): A patient with severe systemic disease that is a constant threat to life
* ASA Score V (American Society of Anesthesiologists classification): A moribund patient who is not expected to survive without the operation
* Emergency/urgency surgery
* Postoperative admission in an intensive care unit with sedation or ventilatory assistance
* Cognitive impairment or mental retardation
* Use of opiods before surgery
* Progressive degenerative diseases of the CNS
* Convulsions or chronic therapy with antiepileptic drugs
* Severe hepatic or renal impairment
* Allergy to one of the specific drugs under study
* Acute infection or inflammatory chronic disease
* Alcohol or drug addiction
* Any kind of communication problem
* Neurologic or psychiatric disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No